CD40 stimulation of CLL cells strongly induces pro-survival Bcl-2 family members, resulting in resistance to conventional chemotherapy [34] as well as novel targeted drugs, such as the specific inhibitor of Bcl-2 venetoclax [35]. The gene discussed is CD40; the disease is B-cell chronic lymphocytic leukemia.